Branded

Lupin is acquiring Brovana inhalation solution and Xopenex HFA inhalation aerosol from Sunovion for $75 million.

Tecvayli, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options.

​​​​​​The approval allows Lannett’s site in Seymour, Ind. to rapidly expand liquid drug manufacturing.

Dyanavel XR is FDA-approved for the treatment of Attention-Deficit Hyperactivity Disorder in patients aged 6 years old and older.

Relyvrio is a treatment option for patients with ALS, commonly referred to as Lou Gehrig’s disease.  

Sotyktu is an oral treatment for adults with moderate-to-severe plaque psoriasis.

Imfinzi is used to treat adult patients with locally advanced or metastatic biliary tract cancer in combination with chemotherapy (gemcitabine plus cisplatin).

Konvomep is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.

Spevigo is the first approved treatment option for generalized pustular psoriasis flares in adults.

Pemazyre is the first targeted treatment approved for use in the United States for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Auvelity is the first and only oral nmda receptor antagonist for the treatment of major depressive disorder in adults.

​​​​​​​Zoryve is a next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis.